Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

1. Breast screening: interval cancers and duty of candour toolkit

Breast screening: interval cancers and duty of candour toolkit Breast screening: interval cancers and duty of candour toolkit - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Show or hide search Search on GOV.UK Search Menu Guidance and support Take action now for new rules in 2021 Guidance (...) Breast screening: interval cancers and duty of candour toolkit Guidance on the role of breast screening and symptomatic services in identifying interval cancer and giving results to female patients. Published 11 December 2017 Last updated 24 November 2020 — From: Documents Ref: PHE Gateway number 2017648 HTML Ref: PHE Gateway number 2017648 PDF , 194KB , 1 page This file may not be suitable for users of assistive technology. Request an accessible format. If you use assistive technology

2020 Public Health England

2. Alpelisib (Piqray) plus fulvestrant for PIK3CA-mutated, hormone receptor–positive advanced breast cancer

Alpelisib (Piqray) plus fulvestrant for PIK3CA-mutated, hormone receptor–positive advanced breast cancer Alpelisib (Piqray®) plus fulvestrant for PIK3CA-mutated, hormone receptor–positive advanced breast cancer - Repository of AIHTA GmbH English | Browse - - - Alpelisib (Piqray®) plus fulvestrant for PIK3CA-mutated, hormone receptor–positive advanced breast cancer Grössmann, N. (2020): Alpelisib (Piqray®) plus fulvestrant for PIK3CA-mutated, hormone receptor–positive advanced breast cancer

2020 Austrian Institute of Health Technology Assessment

3. Magseed for locating impalpable breast cancer lesions

breast cancer. At the time of surgery, Magseed's location is detected with the Sentimag probe (a magnetic sensing system). This sensing machine makes sounds of different pitches and gives a reading to let surgeons know how close they are to Magseed. The seed is then removed along with the tumour. Magseed can be implanted any time before the surgical procedure. The company and 1 expert also noted the use of Magseed to localise axillary lymph nodes in people who are having neoadjuvant chemotherapy (...) A service evaluation comparing the standard practice of guide wires with Magseed for lesion localisation in people having surgery to remove impalpable disease at a single institution in the UK. Intervention and comparator Intervention and comparator Magseed (n=128) compared with wire guided localisation (n=168). Key outcomes Key outcomes The study included 2 consecutive cohorts of people who had wire guided localisation or Magseed. Magseed for locating impalpable breast cancer lesions (MIB236) © NICE

2020 National Institute for Health and Clinical Excellence - Advice

4. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial

Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial - PubMed This site needs JavaScript to work properly. Please enable it to take (...) Actions Cite Display options Display options Format Share Permalink Copy Page navigation Clinical Trial Lancet Oncol Actions . 2020 Oct;21(10):1283-1295. doi: 10.1016/S1470-2045(20)30465-4. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 University of Pittsburgh Medical Center

2020 EvidenceUpdates

5. Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors Full Text available with Trip Pro

(USA) women with postmenopausal breast cancer were included. In both countries, there were higher coronary artery disease risks in AI compared with tamoxifen users (UK age-standardised incidence rate: 10.17 vs 7.51 per 1000 person-years, HR: 1.29, 95% CI 0.94 to 1.76; US age-standardised incidence rate: 36.82 vs 26.02 per 1000 person-years, HR: 1.29, 95% C I1.06 to 1.55). However, comparisons with those receiving no endocrine therapy (US data) showed no higher risk for either drug class and a lower (...) Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public health information from CDC: Get

2020 EvidenceUpdates

6. A fixed-dose combination of pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo) for the treatment of early and metastatic breast cancer

A fixed-dose combination of pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo) for the treatment of early and metastatic breast cancer A fixed-dose combination of pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) for the treatment of early and metastatic breast cancer - Repository of AIHTA GmbH English | Browse - - - A fixed-dose combination of pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) for the treatment of early and metastatic breast cancer Grössmann, N. (2020 (...) ): A fixed-dose combination of pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) for the treatment of early and metastatic breast cancer. Oncology Fact Sheet Nr. 30. Preview - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. , oder 69kB Item Type: Oncology Fact Sheet Subjects: > > > > Language: English Series Name: Oncology Fact Sheet Nr. 30 Deposited on: 09 Dec 2020 11:06 Last Modified: 09 Dec 2020 11:06 Repository Staff Only: © Copyright ,

2020 Austrian Institute of Health Technology Assessment

7. Trastuzumab emtansine (Kadcyla) - human epidermal growth factor-2 (HER2) positive early breast cancer

of ipsilateral invasive breast tumour, recurrence of ipsilateral locoregional invasive breast cancer, contralateral invasive breast cancer, a distant disease recurrence, or death from any cause. Efficacy analyses were performed in the intention-to-treat population (ITT), which included all patients who underwent randomisation. 2, 3 The KATHERINE study met its primary outcome; trastuzumab emtansine was associated with a statistically significant improvement in IDFS compared with trastuzumab in patients (...) in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission trastuzumab emtansine (Kadcyla®) is accepted for use within NHSScotland. Indication under review: As a single agent, for the adjuvant treatment of adult patients with human epidermal growth factor-2 (HER2) positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2 targeted therapy. Trastuzumab emtansine was associated with a statistically

2020 Scottish Medicines Consortium

8. Atezolizumab (Tecentriq) - for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC)

for this indication. Summary of evidence on comparative efficacy In triple-negative breast cancer, tumour cells test negative for oestrogen and progesterone receptors and do not overexpress human epidermal growth factor receptor 2 (HER2). These account for 12 to 20% of all breast cancers and are associated with more aggressive disease and poorer outcomes. Atezolizumab is a humanised monoclonal antibody that binds to programmed death–ligand 1 (PD-L1) and blocks its interactions with the programmed death-1 (PD-1 (...) nab-paclitaxel compared with placebo plus nab-paclitaxel in 902 patients with advanced triple-negative breast cancer, previously untreated for metastatic disease. Study patients were aged =18 years with metastatic or unresectable locally advanced, histologically documented triple-negative breast cancer who had received no previous chemotherapy or targeted therapy for metastatic disease and were eligible for taxane monotherapy. They had tissue evaluable for tumour PD-L1 expression, measurable

2020 Scottish Medicines Consortium

9. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE) Full Text available with Trip Pro

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE) Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE) - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable (...) : 10.1200/JCO.20.02514. Online ahead of print. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE) , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Royal Marsden NHS Foundation Trust, London, United Kingdom. 2 Department of Obstetrics and Gynecology, Breast Center, LMU University Hospital, Munich, Germany. 3 Clinica Pesquisas e Centro São Paulo, São Paulo, Brazil. 4

2020 EvidenceUpdates

10. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial

. Eligible patients (aged ≥18 years) had deleterious germline BRCA1 or BRCA2 mutation-associated, histologically or cytologically confirmed advanced HER2-negative breast cancer, an Eastern Cooperative Oncology Group performance status of 0-2, and had received up to two previous lines of chemotherapy for metastatic disease. Patients were randomly assigned (2:1) by interactive response technology by means of permuted blocks within strata (block size of 3 or 6) to carboplatin (area under the concentration (...) : 10.1038/s41523-020-00197-2. eCollection 2020. NPJ Breast Cancer. 2020. PMID: 33088912 Free PMC article. Review. Publication types Clinical Trial, Phase III Actions Multicenter Study Actions Randomized Controlled Trial Actions Research Support, Non-U.S. Gov't Actions MeSH terms Adult Actions Antineoplastic Combined Chemotherapy Protocols / therapeutic use* Actions Benzimidazoles / therapeutic use* Actions Breast Neoplasms / drug therapy* Actions Breast Neoplasms / genetics Actions Breast Neoplasms

2020 EvidenceUpdates

11. Annual mammographic screening to reduce breast cancer mortality in women from age 40 years: long-term follow-up of the UK Age RCT Full Text available with Trip Pro

Annual mammographic screening to reduce breast cancer mortality in women from age 40 years: long-term follow-up of the UK Age RCT Annual mammographic screening to reduce breast cancer mortality in women from age 40 years: long-term follow-up of the UK Age RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website (...) search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Annual mammography screening at ages 40 49 years conferred a reduction in breast cancer mortality, which was attenuated after 10 years. {{author}} {{($index , , , , , , , , , , , , & . Stephen Duffy 1, * , Daniel Vulkan 1 , Howard Cuckle 2 , Dharmishta Parmar 1 , Shama Sheikh 3 , Robert Smith 4 , Andrew Evans 5 , Oleg Blyuss 1 , Louise Johns 3 , Ian

2020 NIHR HTA programme

12. Autologous fat grafting (AFG) by injection, for defects arising from breast surgery, cancer treatment/prevention or congenital deformity

and congenital breast deformity. The initial proposal to introduce a new MBS item for AFG arose as a recommendation from the Medical Benefits Schedule Review Taskforce. The draft report from the Plastic and Reconstructive Surgery Clinical Committee (PRSCC) recommended a new MBS item for AFG for defects resulting from excision of a breast malignancy, for defects post-mastectomy, or for developmental abnormality. The Breast Cancer Surgery and Reconstruction Working Group, part of the PRSCC, noted that a new (...) . ? Subpopulation A2 - Post mastectomy with suboptimal outcomes after autologous or prosthetic reconstruction. ? Subpopulation A3 - Suboptimal outcomes following breast conserving surgery (BCS) for benign or malignant neoplasms. Population B Developmental breast abnormalities defined as congenital tuberous breast or unilateral hypomastia causing asymmetry with a >20% difference in the contralateral side. Population A clinical management pathway The current clinical practice for managing patients with breast

2020 Medical Services Advisory Committee

13. Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer

allowed according to trial protocol and institutional guidelines. Invasive disease–free survival—defined as freedom from ipsilateral invasive breast tumor recurrence, ipsilateral locoregional invasive breast cancer recurrence, contralateral invasive breast cancer, distant recurrence, or death from any cause—was the primary end point of the trial. TABLE 2. Results of the KATHERINE Open-Label, Phase III Clinical Trial Approximately 18% of patients received dual HER2 targeted therapy with trastuzumab (...) approach to identify new, potentially practice-changing data that might translate into revised guideline recommendations. RESULTS The Expert Panel reviewed abstracts from the literature review and identified one article for inclusion that reported results of the phase III, open-label KATHERINE trial. In the KATHERINE trial, patients with stage I to III human epidermal growth factor receptor 2 (HER2)–positive breast cancer with residual invasive disease in the breast or axilla after completing

2020 American Society of Clinical Oncology Guidelines

14. Targeted intraoperative radiotherapy for early-stage breast cancer

) has an oestrogen-receptor positive tumour; and e) has a node negative malignancy; and f) is suitable for wide local excision of a primary invasive ductal carcinoma that was diagnosed as unifocal on conventional examination and imaging; and g) has no contra-indications to breast irradiation Fee: $250.00 Benefit: 75% = $187.50 2 MBS Item Descriptor 31516 BREAST, MALIGNANT TUMOUR, complete local excision of, with or without frozen section histology when targeted intraoperative radiotherapy (using (...) of a primary invasive ductal carcinoma that was diagnosed as unifocal on conventional examination and imaging; and g) has no contraindications to breast irradiation MBS Fee: $250.00 Benefit: 75% = $187.50 31516 – version 2 BREAST, MALIGNANT TUMOUR, complete local excision of, with or without frozen section histology when targeted intraoperative radiotherapy is performed concurrently, if the requirements of item 15900 are met for the patient (Anaes.) (Assist.) MBS Fee: $867.00 Benefit: 75% = $650.25 Source

2020 Medical Services Advisory Committee

15. Tucatinib (Tukysa) - locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer, including patients with brain metastases

Tucatinib (Tukysa) - locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer, including patients with brain metastases Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related

2020 Health Canada - Drug and Health Product Register

16. Trastuzumab-emtansine (Kadcyla) in adjuvant treatment of adult patients with HER-2 positive breast cancer in an early stage

Trastuzumab-emtansine (Kadcyla®) in adjuvant treatment of adult patients with HER-2 positive breast cancer in an early stage Zorginstituut Nederland has completed its assessment whether trastuzumab-emtansine (Kadcyla®) can be included in the insured package. The treatment is indicated as adjuvant treatment of adult patients with HER2-positive breast cancer in an early stage, who have invasive residual disease after a taxane-based and HER2-focused neoadjuvant treatment. Due to its expected high costs (...) Trastuzumab-emtansine (Kadcyla) in adjuvant treatment of adult patients with HER-2 positive breast cancer in an early stage Trastuzumab-emtansine (Kadcyla®) in adjuvant treatment of adult patients with HER-2 positive breast cancer in an early stage | Report | National Health Care Institute You are here: Trastuzumab-emtansine (Kadcyla®) in adjuvant treatment of adult patients with HER-2 positive breast cancer in an early stage Search within English part of National Health Care Institute Search

2020 National Health Care Institute (Zorginstituut Nederland)

17. Trastuzumab emtansine (breast cancer) - Benefit assessment according to §35a Social Code Book V

Keywords: Ado-Trastuzumab Emtansine, Breast Neoplasms, Benefit Assessment, NCT01772472 Extract of dossier assessment A20-07 Version 1.0 Trastuzumab emtansine (breast cancer) 14 April 2020 Institute for Quality and Efficiency in Health Care (IQWiG) - iii - Table of contents Page List of tables iv List of abbreviations v 2 Benefit assessment 1 2.1 Executive summary of the benefit assessment 1 2.2 Research question 7 2.3 Information retrieval and study pool 8 2.3.1 Studies included 8 2.3.2 Study (...) follows that of the full dossier assessment. Extract of dossier assessment A20-07 Version 1.0 Trastuzumab emtansine (breast cancer) 14 April 2020 Institute for Quality and Efficiency in Health Care (IQWiG) - v - List of abbreviations Abbreviation Meaning ACT appropriate comparator therapy AE adverse event CI confidence interval CTCAE Common Terminology Criteria for Adverse Events DFS disease-free survival DRFI distant recurrence-free interval ECOG PS Eastern Cooperative Oncology Group Performance

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

18. Ribociclib (breast cancer; combination with aromatase inhibitors) - Benefit assessment according to §35a Social Code Book V

in the dossier assessment ? Vanessa Voelskow ? Tatjana Hermanns ? Stefan Kobza ? Katrin Nink ? Sabine Ostlender ? Daniela Preukschat ? Dominik Schierbaum ? Anke Schulz Keywords: Ribociclib, Breast Neoplasms, Benefit Assessment, NCT01958021 Extract of dossier assessment A20-21 Version 1.0 Ribociclib (breast cancer, combination with an aromatase inhibitor) 28 May 2020 Institute for Quality and Efficiency in Health Care (IQWiG) - iii - Table of contents Page List of tables iv List of abbreviations v 2 Benefit (...) patients had an ECOG PS of 1. More than 99% of the study population had stage IV disease, i.e. distant metastasis, on study entry. Disease history and location of the metastases were comparable beyond the stratification factor “presence of liver and/or lung metastases”. Table 10 shows the median observation period for individual outcomes. Extract of dossier assessment A20-21 Version 1.0 Ribociclib (breast cancer, combination with an aromatase inhibitor) 28 May 2020 Institute for Quality and Efficiency

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

19. PD-L1 (Programmed Death Ligand 1) immunohistochemistry (IHC) testing for access to atezolizumab as first line therapy for patients with locally advanced or metastatic triple-negative breast cancer (TNBC)

breast cancer, and there is likely no requirement for most patients to undergo any additional procedures associated with the collection of tumour tissue in order to perform PD-L1 IHC testing. For those with recurrent disease, PD-L1 IHC testing could be performed on archival tumour tissue. However, the Commentary stated that PD-L1 status will differ between the primary tumour and metastases for some patients. Thus, PD-L1 IHC testing should be conducted using new 12 biopsies or surgical tumour samples (...) immune cells (IC) to determine eligibility for treatment with atezolizumab plus a taxane in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC); and • Pharmaceutical Benefits Scheme (PBS) [Authority Required] listing for treatment with atezolizumab plus a taxane for the treatment of patients with unresectable locally advanced or metastatic TNBC who have evidence of PD-L1 expression on IC covering =1% of tumour area. 2. MSAC’s advice to the Minister After

2020 Medical Services Advisory Committee

20. Evaluation of 1-Year vs Shorter Durations of Adjuvant Trastuzumab Among Patients With Early Breast Cancer: An Individual Participant Data and Trial-Level Meta-analysis Full Text available with Trip Pro

a shorter duration with 1 year of trastuzumab as adjuvant treatment, and include patients with early breast cancer. Data extraction and synthesis: Individual patient data for disease-free survival (DFS) and overall survival (OS) were extracted from published survival curves of included RCTs; DFS and OS curves for each trial and the combined population were reconstructed. The DFS and OS hazard ratios (HRs) were estimated from the reconstructed survival curves as well as published estimates. The HR (...) Evaluation of 1-Year vs Shorter Durations of Adjuvant Trastuzumab Among Patients With Early Breast Cancer: An Individual Participant Data and Trial-Level Meta-analysis Evaluation of 1-Year vs Shorter Durations of Adjuvant Trastuzumab Among Patients With Early Breast Cancer: An Individual Participant Data and Trial-Level Meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several

2020 EvidenceUpdates